Kavanaugh A F
University of Texas, Southwestern Medical School, Dallas, USA.
Rheum Dis Clin North Am. 1998 Aug;24(3):593-614. doi: 10.1016/s0889-857x(05)70028-4.
Because it plays a central role in the immunopathogenesis of rheumatoid arthritis (RA), TNF-alpha is an attractive target for immunomodulatory therapy. In a number of rigorous studies, monoclonal antibodies (mAb) specific for TNF-alpha have proved efficacious in patients with active RA. Data from these studies and issues related to mechanisms of action, potential toxicity, and future directions for this novel therapeutic approach are considered in this review.
由于肿瘤坏死因子-α（TNF-α）在类风湿关节炎（RA）的免疫发病机制中起核心作用，因此它是免疫调节治疗的一个有吸引力的靶点。在多项严谨的研究中，针对TNF-α的单克隆抗体（mAb）已被证明对活动性RA患者有效。本文综述将探讨这些研究的数据以及与这种新型治疗方法的作用机制、潜在毒性和未来方向相关的问题。
